Uterine Sarcomas Versus Leiomyomas: Gray-scale and Doppler Sonographic Findings
Overview
Authors
Affiliations
Purpose: The aim of the study was to evaluate the contribution of gray-scale sonography and Doppler flow studies in differentiating between uterine sarcomas of different histologic types and leiomyomas.
Patients And Methods: The study included 111 patients, divided retrospectively into 2 groups: 98 patients with leiomyomas and 13 with postoperative diagnosis of uterine sarcoma. This latter group was further divided into a group of 6 patients with uterine leiomyosarcoma and 7 with malignant mixed mesodermal tumor. The gray-scale sonograms and Doppler parameters in the 3 groups were compared.
Results: The patients with leiomyomas were younger than those with sarcomas (52 years +/- 11 versus 65 years +/- 15, p < 0.05). No differences were noted between the 3 groups regarding gravidity, parity, symptoms upon admission, or findings during physical examination. The sonographic appearances of the leiomyomas were similar to those of the leiomyosarcomas, but in 6/7 cases, they were different from those of the malignant mixed mesodermal tumors. There was a significant difference between the mean resistance index in arterioles of the leiomyomas (0.59 +/- 0.01) and that of the malignant mixed mesodermal tumors (0.41 +/- 0.06) (P < 0.001) but not between those of the leiomyomas and the leiomyosarcomas (0.49 +/- 0.18).
Conclusions: Doppler flow studies may assist in differentiating between leiomyomas and malignant mixed mesodermal tumors but not between leiomyomas and leiomyosarcomas.
Cabezas N, Lopez-Picazo A, Diaz P, Valero B, Rodriguez M, Redondo A Diagnostics (Basel). 2023; 13(3).
PMID: 36766608 PMC: 9914371. DOI: 10.3390/diagnostics13030501.
MRI Evaluation of Uterine Masses for Risk of Leiomyosarcoma: A Consensus Statement.
Hindman N, Kang S, Fournier L, Lakhman Y, Nougaret S, Reinhold C Radiology. 2022; 306(2):e211658.
PMID: 36194109 PMC: 9885356. DOI: 10.1148/radiol.211658.
Advances in the Preoperative Identification of Uterine Sarcoma.
Liu J, Wang Z Cancers (Basel). 2022; 14(14).
PMID: 35884577 PMC: 9318633. DOI: 10.3390/cancers14143517.
Zak K, Zaremba B, Rajtak A, Kotarski J, Amant F, Bobinski M Cancers (Basel). 2022; 14(8).
PMID: 35454875 PMC: 9029111. DOI: 10.3390/cancers14081966.
Surace A, Bau M, Privitera S, Botta G, Danese S, Plazzotta C Int J Gynaecol Obstet. 2021; 156(2):236-239.
PMID: 33834486 PMC: 9291939. DOI: 10.1002/ijgo.13701.